Cargando…

Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies

Myelofibrosis (MF) is a clonal hematopoietic stem cell disorder characterized by pathological myeloproliferation and aberrant cytokine production resulting in progressive fibrosis, inflammation, and functional compromise of the bone marrow niche. Patients with MF develop splenomegaly (due to extrame...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naymagon, Leonard, Mascarenhas, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745971/ https://www.ncbi.nlm.nih.gov/pubmed/31723730 http://dx.doi.org/10.1097/HS9.0000000000000001

Ejemplares similares

Next Generation Therapeutics for the Treatment of Myelofibrosis
por: Tremblay, Douglas, et al.
Publicado: (2021)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Emerging Treatment Options for Myelofibrosis: Focus on Anemia
por: Sastow, Dahniel, et al.
Publicado: (2023)

Current and emerging therapeutic strategies for Fanconi anemia
por: Shukla, Pallavi, et al.
Publicado: (2012)

Primary myelofibrosis: current therapeutic options
por: de Melo Campos, Paula
Publicado: (2016)

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Novel therapeutics for myelofibrosis
por: Lee, Sung-Eun
Publicado: (2023)

P1059: REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION IN MYELOFIBROSIS PATIENTS WITH ANEMIA
por: Mascarenhas, John, et al.
Publicado: (2023)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Plasmodium falciparum-Induced Autoimmune Hemolytic Anemia in a Pregnant Patient with Sickle Cell Disease
por: Rupani, Karishma Vijay, et al.
Publicado: (2023)

Treatment of Myelofibrosis: Old and New Strategies
por: Iurlo, Alessandra, et al.
Publicado: (2017)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
por: Hatzimichael, Eleftheria, et al.
Publicado: (2022)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

Biological drivers of clinical phenotype in myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2022)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

Emerging treatment options for myelofibrosis: focus on pacritinib
por: Chow, Vivian, et al.
Publicado: (2016)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
por: Sochacki, Andrew L, et al.
Publicado: (2016)

Novel agents in the treatment of multiple myeloma: a review about the future
por: Naymagon, Leonard, et al.
Publicado: (2016)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism
por: Sethi, Sidharth Kumar, et al.
Publicado: (2018)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
por: Cervantes, Francisco, et al.
Publicado: (2021)

Anakinra for the treatment of adult secondary HLH: a retrospective experience
por: Naymagon, Leonard
Publicado: (2022)

Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs
por: Liu, Angela, et al.
Publicado: (2022)

Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies
por: Germing, Ulrich, et al.
Publicado: (2019)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

Anemia in myelofibrosis—prevalence, the U2AF1 connection, new treatments
por: Tefferi, Ayalew
Publicado: (2017)

Current evidence and the emerging role of eltrombopag in severe aplastic anemia
por: Drexler, Beatrice, et al.
Publicado: (2021)

Murine Models of Myelofibrosis
por: Jacquelin, Sebastien, et al.
Publicado: (2020)

Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies
por: Abedalthagafi, Malak
Publicado: (2018)

The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms
por: Bjørn, Mads Emil, et al.
Publicado: (2015)

COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies
por: Feng, Gong, et al.
Publicado: (2020)

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
por: Cervantes, Francisco, et al.
Publicado: (2021)

Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
por: Perram, Jacinta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ri66ra5u54l8mj7jbmqjm241c6